Liquidia settles six United Therapeutics lawsuits for $380.7 million
Liquidia announced a global settlement with United Therapeutics resolving six ongoing lawsuits. Liquidia will make net payments totaling $380.70 million in installments during 2026 and 2027, including $175 million to United Therapeutics within 30 business days. Yutrepia will remain available to patients with pulmonary arterial hypertension without disruption, while Liquidia removes the pulmonary hypertension associated with interstitial lung disease indication from the label and ceases promotion for that use.
The provided Reuters item directly supports a new global settlement resolving six ongoing lawsuits between Liquidia and United Therapeutics. The settlement creates substantial forward-looking cash obligations totaling $380.70 million in 2026 and 2027, including $175 million payable to United Therapeutics within 30 business days, while preserving Yutrepia availability for PAH but removing its PH-ILD indication and ending promotion for that use. This is best classified as a legal_dispute because the central development is the resolution of litigation; the associated payment and product terms are material consequences of that resolution. The date is explicit, while the time is estimated from the source timestamp. Only LQDA and UTHR are approved stakeholders because they are the direct parties to the settlement; more distant competitors, payers, and suppliers have indirect and insufficiently certain effects. The development is a resolution milestone within the existing United Therapeutics–Liquidia Yutrepia litigation storyline and is not a duplicate of the prior infringement ruling.
- LIQUIDIA ANNOUNCES GLOBAL SETTLEMENT RESOLVING ALL PENDING LITIGATION WITH UNITED THERAPEUTICS, ENSURING CONTINUED COMMERCIALIZATION OF YUTREPIA IN PAH
- LIQUIDIA CORPORATION - SETTLEMENT FULLY RESOLVES SIX ONGOING LAWSUITS BETWEEN LIQUIDIA AND UNITED THERAPEUTICS
- LIQUIDIA CORPORATION - TO PAY NET $380.70 MILLION IN INSTALLMENTS IN 2026 AND 2027
- LIQUIDIA CORPORATION - TO PAY $175 MILLION TO UNITED THERAPEUTICS WITHIN 30 BUSINESS DAYS
Liquidia announced a global settlement with United Therapeutics resolving all litigation over Yutrepia.
The deal keeps Yutrepia available for PAH while removing the PH-ILD indication and related promotion.
Liquidia will pay United Therapeutics $175.0 million within 30 business days and $145.4 million in two installments in 2027
United Therapeutics reached a settlement with Liquidia resolving multiple patent and related litigations, including a $330.4 million aggregate payment to United Therapeutics and actions to remove the PH-ILD indication from Yutrepia’s label.
Liquidia will pay United Therapeutics $330.4M total: $185M within 30 business days and $145.4M in two installments.
Liquidia must file an FDA label amendment to remove the PH-ILD indication and cease PH-ILD promotion immediately.